Circulating Cell-Free Nucleic Acids and Cancers: 3rd Edition
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 30 December 2025 | Viewed by 306
Special Issue Editor
Interests: biological fluids; cancer; cancer biomarkers; cfDI; cfDNA; cfNA; copy number variation; ctDNA; ddPCR; disease-free survival; epigenetic; epigenetic sequencing; exosome; extracellular vesicle; genotyping; liquid biopsy; miRNA; mRNA; mutation; ncRNA; next- generation sequencing; overall survival; progression-free survival; recurrence-free survival; whole-exome sequencing
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is a continuation of our previous Special Issue, “Circulating Cell-Free Nucleic Acids and Cancers: 2nd Edition”. Improvements in the molecular diagnosis and prognosis of cancer and better evaluation of therapeutic intervention are urgently needed to offer more personalized treatment to patients.
In this respect, liquid biopsy shows great potential in precision medicine, especially for solid tumors. It is applicable for screening, diagnosis, prognosis, and for predictive value and monitoring of the disease. Liquid biopsy is a versatile and minimally invasive procedure, and the availability of high-throughput technologies allows for the analysis of very small quantities of targets.
In liquid biopsy, targeting circulating cell-free nucleic acid (cfNA) is one of the most interesting aspects because many cancer biomarkers, already identified in the tissue, can be found in circulating cell-free DNA (cfDNA). In cfDNA, a fraction of tumor DNA (ctDNA) can be searched by identifying both the cancer-related mutations and the copy number variation of specific genes. The cancer-related methylation status of selected genes in cfDNA can also be measured. Moreover, it has been demonstrated that ctDNA quantity can be related to the integrity index of the cfDNA, (cfDI), i.e., the fraction of long over short-nested fragments of the same DNA target. Many studies indicate that ctDNA analysis can depict tumor heterogeneity. Recently, the role of circulating-free RNA molecules (cfRNA) in diagnosis, prognosis, and therapy responsiveness is emerging. In general, studies on cfNA have a high translational potential for clinical practice, as in EGFR mutations validated by FDA in 2016 for NSCLC. Finally, the analysis of cfNA has the advantage of being highly specific but simpler and lower costing than analyses using circulating tumor cells. Thus, they can be useful to facilitate therapeutic decision making and to predict tumor burden after therapies or the acquired treatment resistance.
Topics of interest for this Special Issue include, but are not limited to, the following:
- Liquid biopsy targeting cfNA for cancer molecular diagnostics;
- Clinical validity and utility of cfNA analysis for tumors;
- Epigenetic markers for cancer by liquid biopsy;
- Extracellular vesicle biomarkers in liquid biopsy;
- New insights in cfNA biomarkers (cfDNA, ctDNA, cfDI and cfRNA) for the screening, diagnosis, prognosis, follow-up, and therapeutic management of tumors;
- New techniques to evaluate cfNA;
- Liquid biopsy on exosome for cancer diagnostics.
Dr. Bruna Scaggiante
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biological fluids
- cancer
- cancer biomarkers
- cfDI
- cfDNA
- cfNA
- copy number variation
- ctDNA
- ddPCR
- disease-free survival
- epigenetic
- epigenetic sequencing
- exosome
- extracellular vesicle
- genotyping
- liquid biopsy
- miRNA
- mRNA
- mutation
- ncRNA
- next-generation sequencing
- overall survival
- progression-free survival
- recurrence-free survival
- whole-exome sequencing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
